Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Short bowel syndrome


See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Management Guidelines

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Short bowel syndrome. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Teduglutide [rDNA origin]
Trade Name
(Manufacturer Name)
Gattex
(NPS Pharmaceuticals, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support
More Information about this product Drug Information Portal

Generic Name Glutamine
Trade Name
(Manufacturer Name)
NutreStoreā„¢
(Emmaus Medical Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a rercombinant human growth hormone that is approved for this indication.
More Information about this product Drug Information Portal

Generic Name Somatropin (r-DNA)
Trade Name
(Manufacturer Name)
Zorbtive®
(EMD Serono, Inc.)
Indication
The FDA has approved this product to be used in this manner.
Treatment of short bowel syndrome in patients receiving specialized nutritional support
More Information about this product Drug Information Portal

See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.